Gene Therapy Breakthrough Restoring Sight and Changing Lives

Scientists are making big strides in genetic medicine, bringing hope to people with vision loss. A recent breakthrough focuses on Leber hereditary optic neuropathy (LHON), a rare condition that leads to blindness. According to an article from U.S. News & World Report, researchers used gene therapy to inject healthy copies of the MT-ND4 gene into the eye. This treatment improved vision in patients, offering a life-changing solution for those who once had no options.

Another exciting development, reported by Science Daily, explores how gene therapy is helping people with Leber congenital amaurosis (LCA), a condition that causes severe vision loss in childhood. In a trial by the University of Pennsylvania, patients treated for a mutation in the GUCY2D gene experienced massive improvements in their ability to see in low light, some up to 10,000 times better! These breakthroughs highlight how genetic therapy is quickly becoming a game-changer for treating vision problems.

These discoveries show how powerful gene therapy can be. Fixing faulty genes could improve the lives of people with genetic conditions, restoring not just vision but also independence and confidence. Of course, there are still hurdles, like making sure these treatments are safe, accessible, and affordable for everyone who needs them.

To me, this research is incredible. It shows how science can solve problems that seemed impossible just a few years ago. Restoring vision is more than a medical achievement, it’s giving people their lives back. I’m excited to see what’s next for gene therapy and how it might help with even more genetic conditions.

SITES USED

https://www.usnews.com/news/health-news/articles/2024-09-06/gene-therapy-reverses-a-rare-cause-of-vision-loss    

https://www.sciencedaily.com/releases/2024/09/240906141608.htm

New Gene-Based Therapy Partially Restored a Blind Man’s Vision

Retinitis pigmentosa is a rare genetic disease that people are born with- it causes the light-gathering cells in the retina to die resulting in vision loss over time. There is no known cure for retinitis pigmentosa, but scientists announced in their report in the journal Nature Medicine that they partially restored a blind man’s sight by using a new technique called optogenetics.

Before the optogenetic therapy treatment, the man could detect some light but could not see motion or pick out objects- now he can see and count objects, and even reported being able to see the white stripes of a pedestrian crosswalk! His vision is still limited and requires him to wear special goggles, but his results are proof of more effective treatments to come.

For people with degenerative eye diseases, the therapy involved uses a light-sensitive protein to make nerve cells fire off a signal to the brain when hit with a certain wavelength of light. These therapies may halt or slow progression of degenerative eye diseases, but it does not help people who have already lost vision. This is simply because when victims lose their photoreceptors completely- you cannot repair the gene defect from dead cells.

In this new optogenetic therapy treatment, researchers have been experimenting with a radical kind of repair- they are using gene therapy to turn ganglion cells into new photoreceptor cells, even though they do not normally capture light. Scientists are taking advantage of proteins derived from algae and other microbes that can make any nerve cell sensitive to light. In the early 2000s, neuroscientists figured out how to install some of these proteins into the brain cells of mice and other lab animals by injecting viruses carrying their genes. The viruses infected certain types of brain cells, which then used the new gene to build light-sensitive channels. Now, Dr. Sahel and other researchers are using optogenetics to add light-sensitive proteins to cells in the retina. They reason that retinal cells are nerves as well- or in other words, an extension of the brain.

To create their goggles, scientists chose an optogenetic protein that is sensitive only to amber light, which is easier on the eye than other colors, and used viruses to deliver these amber proteins to the ganglion cells in the retina. A special device was used to transform visual information from the external world into amber light that could be recognized by the ganglion cells. The goggles then send a pulse of amber light from that pixel into the eye thus activating parts of the brain involved in vision.

Even though it will take many more positive results from clinical trials before optogenetics can become a standard treatment for some forms of blindness, there is no doubt that this opens up a new world for the lives of individuals with vision impairment. Certainly this is an exciting time for scientists and researchers involved in the field of vision and vision treatment, and I am interested in seeing how optogenetic therapy progresses.







Sources:
https://www.nytimes.com/2021/05/24/science/blindness-therapy-optogenetics.html

https://www.sciencenews.org/article/blindness-retinitis-pigmentosa-gene-therapy-vision-optogenetics

https://www.nature.com/articles/s41591-021-01351-4

The loss of vision can be a devastating condition, and there are few options for those affected. According to the article “With single gene insertion, blind mice regain sight,” over 170 million people around the globe face macular degeneration, and the only viable treatment option is an electronic implant. A team at the University of California Berkeley, however, has sought to advance the technology and procedures available to treat vision loss. After having tried for over a decade to devise an effective treatment, the researchers found that inactive viruses could be used as vessels to insert useful genes. Specifically in mice, insertion of opsins, or photosensitive protein-coupled receptors, into living tissue layers of the eye led to the recovery of a limited, but useful amount of vision. Although the result is not yet perfect, trials with the mice showed that they could distinguish parallel from horizontal lines, navigate through a maze just as easily as mice without vision impairments. In addition, the researchers were surprised to find that their sensitivity to light was developed enough to be able to recognize the light from an Ipad rather than brighter LEDs used in other less successful trials.

Through the hope gained through this trial, the team at UC Berkeley have set their sights on helping people regain color vision, and also gaining approval to test their new method with opsins in humans in the coming years. Other studies are concurrently being done to understand which genes are specifically responsible for the loss of vision in children, and by gaining a better grasp of this there can potentially be further advances in gene therapy to mitigate this issue.